Clinical trial · Interventional
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
NCT01596699CI-TRIAL-00043659terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Triggering of futility rule; Interim analysis suggested no statistical superiority over historic controls
Summary
Brief summary (as posted)
The purpose of this study is to find out what effects, good and/or bad, the addition of clofarabine, a new chemotherapy agent, to a standard busulfan and fludarabine conditioning treatment has. The study will also look at what causes some people to have high drug levels of these medications in their body compared to other people that may have low drug levels even if they all receive the same dose of medication.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Failure Syndrome | — | UNRESOLVED | — |
| Congenital Immunodeficiency | — | UNRESOLVED | — |
| Metabolic Disease | — | UNRESOLVED | — |
| Myeloid Malignancy | — | UNRESOLVED | — |
| Severe Immune Dysregulation | — | UNRESOLVED | — |
| Transfusion-dependent Red Blood Cell (RBC) Defect | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alemtuzumab | Drug | Alemtuzumab | ALIAS |
| Busulfan | Drug | Busulfan | ALIAS |
| Clofarabine | Drug | Clofarabine | ALIAS |
| Fludarabine | Drug | Fludarabine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Patients with Myeloid Malignancies
- interventionNames
- Drug: Busulfan
- Drug: Fludarabine
- Drug: Clofarabine
- type
- EXPERIMENTAL
- label
- Patients with Non-Malignancies
- interventionNames
- Drug: Alemtuzumab
- Drug: Busulfan
- Drug: Fludarabine
- Drug: Clofarabine
Primary outcomes (1)
- measure
- Number of Participants With Treatment-Related Adverse Events as a Measure of Safety and Tolerability
- timeFrame
- Up to 5 years on average
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Months
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be ≥ 3 months and ≤30 years of age. * Stratum A: Non-Malignant Diseases, including: * Bone Marrow Failure Syndromes * Hemoglobinopathies or transfusion-dependent red blood cell (RBC) defects * Congenital Immunodeficiencies * Metabolic Diseases known to be treatable with Hematopoietic cell transplantation (HCT) (e.g. Hurler's) * Other Bone Marrow Stem Cell Defects (e.g. Osteopetrosis) * Severe Immune Dysregulation / Autoimmune Syndromes with at least transient prior response to immunosuppressive therapy * Stratum B: Myeloid Malignancies, including: * acute myeloid leukemia (AML), in greater than first clinical remission, or in CR1 but with detectable disease (≥0.1% Blasts by minimal residual disease (MRD) or Flow, or Positive Cytogenetics), or in CR1 but with a matched sibling Umbilical cord blood (UCB) donor. * Myelodysplastic syndromes (MDS) * Juvenile myelomonocytic leukemia (JMML) * Chronic myeloid leukemia (CML), with detectable disease by polymerase chain reaction (PCR) * Patients must have a suitable donor based on the University of California, San Francisco (UCSF) Pediatric Bone Marrow Transplant (BMT) standard operating procedures (SOP). 10/10 (HLA-A, -B, -C, -DR, -DQ) matching will be done for related and adult unrelated donors; 8/8 (HLA-A, -B, -C, -DR) for umbilical cord blood donors. Patients with non-malignant diseases will generally be eligible only if they have a mismatched donor, or an accepted clinical reason to be considered high-risk for rejection. * Liver transaminases (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)) and Direct Bilirubin less than twice the upper limit of normal within 2 weeks of admission. * Cardiac Shortening Fraction ≥27% within 4 weeks of admission. * Creatinine clearance by Schwartz formula, glomerular filtration rate (GFR) or 24 hr urine collection ≥50 cc/min/1.73 m2, within 4 weeks of admission. * Pulmonary diffusion capacity ≥50% of predicted corrected for anemia/lung volume within 4 weeks of admission. If unable to do Pulmonary function testing(PFTs), then no active lung disease by chest x-ray (CXR) and/or oxygen (O2) Saturation ≥90% on room air. Exclusion Criteria: * Fanconi Anemia * Dyskeratosis Congenita * A known syndrome with increased sensitivity to radiation or alkylating agents * Severe Combined Immunodeficiency Disease eligible for a non-myeloablative HCT Trial * A mismatched donor for whom ex vivo T-cell depletion of the donor stem cells is planned
References
Publications (0)
Data not yet available
No reference posted for this study.